1-1 of 1 results for subject:Forgery
Librarians' tools
- Search time
- 0.208 seconds
- Solr query time
- 0.002 seconds
- Search query
- subject:Forgery
- We searched for
- subject_t:Forgery OR subject_ses:91337
Answering member
X
Baroness Winterton of Doncaster
Type
House
Session
Year
Department
Member
Primary member
Answering member
More
Winterton of Doncaster, Baroness (1)
Legislative stage
Legislation
Subject
Publisher
To ask the Secretary of State for Trade and Industry, what steps her Department is taking to tackle counterfeiting in the pharmaceutical industry.
To ask the Secretary of State for Trade and Industry, what steps her Department is taking to tackle counterfeiting in the pharmaceutical industry.
Asked by
John Robertson
(Labour)
Answered by
Baroness Winterton of Doncaster
(Labour)
Answering body
Department of Health
Type
Written questions
Status
Answered
Tabled on
8 November 2004
For answer on
16 November 2004
Answered on
16 November 2004
John Robertson: To ask the Secretary of State for Trade and Industry what steps her Department is taking to tackle counterfeiting in
the pharmaceutical industry. [197472]
Ms Rosie Winterton: I have been asked to reply.
The Medicines and Healthcare products Regulatory Agency (MHRA) investigates all allegations of counterfeit medicines in the United
Kingdom, the vast majority of which are not associated with the tightly regulated legitimate supply chain. Action, in the form of
legal proceedings, is taken when appropriate.
The MHRA's inspection and enforcement division continually reviews its counterfeit strategy in order to remain proactive in this
area. Some of the key initiatives are: The MHRA, in association with the Royal Pharmaceutical Society of Great Britain, routinely
carries out market surveillance by sampling and testing `off the shelf medicines on the UK market for authentication. The target
products for this surveillance are based on intelligence and risk assessments. To date, none of the tests has identified a
counterfeit product. Due to the global nature of the problem of counterfeit medicines, the MHRA continues to liaise closely with
international regulatory partners, the pharmaceutical industry and international law enforcement agencies to ensure that the
tackling of counterfeiting medicines remains a prioritised and co-ordinated activity. The MHRA is actively consulting with the
pharmaceutical industry and technology the providers in the area of its work on technical developments in product security, which
are aimed to further safeguard the integrity of the medicines supply chain. This includes work with the National Patient Safety
Agency and the NHS Patient and Supply Agency on the potential use of bar- coding medicines and blood products to increase patient
safety. In addition, work is being done with the United States Food and Drug Administration in the use of sophisticated
`fingerprinting' to identify active pharmaceutical ingredients as a means of product verification. The MHRA is developing an
educational program for the public and other stakeholders on the dangers of counterfeit medicines and purchasing drugs on the
internet.
Subjects
Counterfeit manufacturing; Forgery; Drugs; Pharmacy; Prescription drugs; Medicine
Date
16 November 2004
Reference
426 c1301W;426 c1305W; 197472
House
House of Commons